[1] Beuers U,Trauner M,Jansen P,et a1.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR,PXR and beyond.J Hepatol,2015,62(IS):S25-S37.
[2] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015).实用肝脏病杂志,2016,19(6):Ⅰ-Ⅺ.
[3] European Association for the Study of the Liver.EASL clinical practice guidelines:Management of cholestatic liver diseases.J Hepatol,2009,51(2):237-267.
[4] Burt AD,Portman BC,Ferrell LD.Mac Sween's pathology of the liver. 6th ed.Spriger Medizin Verlag Herdelberg,2012:503-562.
[5] Bacon BR,O’Grady JG,Di Biscglie AM,et al.Comprehensive clinical hepatology.2nd ed.Elsiver,2006:87.
[6] Greupink R,Nabuurs SB,Zarzycka B,et al.In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity.Toxicol Sci,2012,129(1):35-38.
[7] Jang JH,Rickenbacher A,Humar B,et al.Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation.J Hepatol,2012,56(1):209-218.
[8] Simko V,Michael S,Prego V.Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.J Gastroenterol,1994,89(3):392-398.
[9] O'Shea RS,Dasarathy S,Mc Cullough AJ,et al.Practice parameters committee of the American College of Gastroenterology.J Hepatol,2010,51(1):307-328.
[10] Neuschwander-Tetri BA,Loomba R,Sanyal AJ,et al.FarnesoidX nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis (FLINT):a multicentre,randomised,placebo-controlled trial. Lancet,2015,385:956-965.
[11] 胆汁淤积性肝病诊断治疗专家委员会. 胆汁淤积性肝病诊断治疗专家共识2013. 中国肝脏病杂志,2013,4(1):53-64.
[12] Williamson C,Hems LM,Goulis DG,et al.Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group.BJOG,2004,111:676-681.
[13] Paumgartner G,Pusl T.Medical treatment of cholestatic liver disease.Clin Liver Dis,2008,12(1):53-80.
[14] Trauner M,Halilbasic E,Kazemi-Shirazi L,et al.Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.Dig Dis,2014,32:631-636.
[15] Zhang Y,Lu L,Victor DW,et al.Ursodeoxycholic acid and S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy:A Meta-analysis.Hepat Mon,2016,16(8):e38558.
[16] Yang X.S-adenosyl-methionine for the treatment of drug-induced liver disease in 20 patients.World Chin J Digestol,2001,9:807.
[17] Chianale J,Vollrath V,Wielandt AM,et al.Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.Biochem J,1996,314(3):781-786.
[18] Levy C,Peter JA,Nelson DR,et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.Aliment Pharmacol Ther,2011,33:235-242.
[19] Zhao Q,Yang R,Wang J,et al.PPARαactivation protects against cholestatic liver injury.Sci Rep,2017,7(1):9967.
[20] Cheung AC,Lapointe-Shaw L,Kowgier M,et al.Combined ursodeoxycholic acid(UDCA) and fenofibrate in primary biliarycholangitis patients with incomplete UDCA response may improve outcomes.Aliment Pharmacol Ther,2016,43:283-293.
[21] 王润华.GALLE-DONAU(加诺)的基础研究及临床应用.中国医院用药评价与分析,2002,2(4):226-227. |
